Recent advancements in treating EGFR-mutated NSCLC: in conversation with Mary O’Brien
In this video interview, Consultant Medical Oncologist Mary O’Brien (Royal Marsden Hospital, London, UK) explores current treatment strategies for EGFR-mutated non-small cell lung cancer (NSCLC). O’Brien examines the clinical benefits and associated toxicities of combining chemotherapy with osimertinib in this patient population, highlighting how this approach has significantly extended survival outcomes. She also provides a valuable historical perspective, noting that smoking cessation has had the most profound impact on reducing lung cancer mortality, suggesting that screening for early detection may be key to achieving the next major improvement in lung cancer outcomes.
SAVE THE DATE – 17th November 2027 – The 10th Royal Marsden Lung Cancer Symposium.
Interviewee profile: Dr O’Brien has both a private and an NHS practice at The Royal Marsden. She was born in Northern Ireland and studied medicine at Trinity College Dublin.
Dr O’Brien treats lung cancer, including mesothelioma. She is the former Head of the Lung Unit, past chair of the SWL lung cancer tumor working group, chair of the EORTC lung cancer group, and principal investigator of a number of European trials.
She is interested in all aspects of treatment development through clinical trials. She is also interested in the supportive treatment of cancer patients, including the use of acupuncture for breathlessness.
The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Oncology Central or Taylor & Francis Group.